[go: up one dir, main page]

WO2010048264A3 - Methods and compositions for the treatment of immunoinflammatory disorders - Google Patents

Methods and compositions for the treatment of immunoinflammatory disorders Download PDF

Info

Publication number
WO2010048264A3
WO2010048264A3 PCT/US2009/061446 US2009061446W WO2010048264A3 WO 2010048264 A3 WO2010048264 A3 WO 2010048264A3 US 2009061446 W US2009061446 W US 2009061446W WO 2010048264 A3 WO2010048264 A3 WO 2010048264A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
immunoinflammatory disorders
nortriptyline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/061446
Other languages
French (fr)
Other versions
WO2010048264A2 (en
Inventor
Mahesh V. Padval
Todd W. Chappell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CombinatoRx Inc filed Critical CombinatoRx Inc
Publication of WO2010048264A2 publication Critical patent/WO2010048264A2/en
Publication of WO2010048264A3 publication Critical patent/WO2010048264A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention features a method for treating a patient diagnosed with, or at risk of developing, a dermal immunoinflammatory disorder by topically administering to the patient loratadine and nortriptyline. The invention also features a topical dosage forms containing loratadine and nortriptyline.
PCT/US2009/061446 2008-10-23 2009-10-21 Methods and compositions for the treatment of immunoinflammatory disorders Ceased WO2010048264A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10788508P 2008-10-23 2008-10-23
US61/107,885 2008-10-23

Publications (2)

Publication Number Publication Date
WO2010048264A2 WO2010048264A2 (en) 2010-04-29
WO2010048264A3 true WO2010048264A3 (en) 2010-08-19

Family

ID=42119950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061446 Ceased WO2010048264A2 (en) 2008-10-23 2009-10-21 Methods and compositions for the treatment of immunoinflammatory disorders

Country Status (1)

Country Link
WO (1) WO2010048264A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2549987C1 (en) * 2014-06-17 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Agent for accelerating wound healing and tissue regeneration
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition
DE102017215154A1 (en) * 2017-08-30 2019-02-28 Markus Bläss Composition for the topical treatment of non-microorganism-caused inflammatory skin and mucous membrane diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006026A1 (en) * 2001-07-09 2003-01-23 Combinatorx, Incorporated Combinations for the treatment of inflammatory disorders
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006026A1 (en) * 2001-07-09 2003-01-23 Combinatorx, Incorporated Combinations for the treatment of inflammatory disorders
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions

Also Published As

Publication number Publication date
WO2010048264A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EA201590655A1 (en) COMBINATION OF LACHINIMODE AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
WO2011008931A3 (en) Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EA201001771A1 (en) RELAXIN TREATMENT TREATMENT ASSOCIATED WITH ACUTE HEALTH INSUFFICIENCY
WO2007085019A3 (en) Methods of treating or preventing sinusitis with oxidative reductive potential water solution
WO2013061161A3 (en) New combination therapies for treating neurological disorders
EA201290041A1 (en) TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES
MX2010006823A (en) Methods for the treatment of gout.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2009140657A3 (en) Method of treating chronic heart failure
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2012015758A3 (en) Methods of treating pain
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
WO2012142300A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2011019963A3 (en) Prg4 treatment for interstitial cystitis
BR112012007888A2 (en) "methods of treatment using oxidized anti-ldl antibodies".

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822610

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822610

Country of ref document: EP

Kind code of ref document: A2